IGF-1 LR3 1mg

Description

IGF-1 LR3 Technical Overview

IGF-1 LR3, also known as Long R3 IGF-I, is a synthetic analogue of insulin-like growth factor 1 (IGF-1). Its molecular structure contains an extended N-terminal region and an arginine substitution at the position corresponding to the third residue of mature IGF-1.

These modifications alter interactions with certain insulin-like growth factor binding proteins (IGFBPs), making IGF-1 LR3 a research compound of interest in growth factor signaling and cellular biology.

Experimental investigations involving Long R3 IGF-I have examined receptor activation, protein-binding interactions, cellular proliferation, and growth factor responses in defined laboratory models.

Compound Specifications

Complete sequence, molecular mass, disulfide connectivity, and production method should correspond to the specific Long R3 IGF-I preparation.

Storage and Handling

• Follow the manufacturer’s recommended stability conditions.
• Protect the compound from moisture and unnecessary light exposure.
• Minimize temperature fluctuations and contamination.
• Use appropriate procedures for disulfide-containing protein preparations.

Lyophilized Format

IGF-1 LR3 may be manufactured as a lyophilized research protein. The formulation and stability of the supplied preparation depend on production methods, excipients, and storage conditions.

Research Use Disclaimer

IGF-1 LR3 is an experimental research compound and is not FDA-approved for human therapeutic use. Not intended for human or veterinary administration.

Frequently Asked Questions

What Is IGF-1 LR3?

IGF-1 LR3 is a modified 83-amino-acid analogue of IGF-1 developed for research into growth factor signaling.

How Does IGF-1 LR3 Differ From IGF-1?

It contains an additional N-terminal sequence and an amino acid substitution that alter its interactions with IGF-binding proteins.

What Receptor Is Associated With IGF-1 LR3?

Its principal research receptor is IGF-1R.

Is IGF-1 LR3 the Same as IGF-DES?

No. IGF-DES is a truncated IGF-1 derivative, whereas IGF-1 LR3 is an extended and modified analogue.

Is IGF-1 LR3 FDA-Approved?

No. IGF-1 LR3 is not FDA-approved for therapeutic use.

Research Overview

Long R3 IGF-I has been used in laboratory research to investigate the effects of modified growth factor binding characteristics on cellular responses.

IGF-1 Receptor Signaling

Experimental studies investigate IGF-1R-associated signaling and cellular responses to growth factor exposure.

IGF-Binding Protein Research

The structural modifications of Long R3 IGF-I reduce its affinity for certain IGF-binding proteins, providing a model for studying growth factor availability.

Cellular Proliferation Research

Long R3 IGF-I has been studied in cultured-cell models examining proliferation and growth factor-dependent responses.

Protein Structure Research

Comparisons with native IGF-1 help characterize relationships between protein sequence, binding affinity, and experimental activity.

Research Applications

References

1. Francis GL, Ross M, Ballard FJ, et al. (1992). Novel Recombinant Fusion Protein Analogues of Insulin-Like Growth Factor (IGF)-I Indicate the Relative Importance of IGF-Binding Protein and Receptor Binding for Enhanced Biological Potency. Journal of Molecular Endocrinology. Publication information.

Certificate of Analysis (COA)

Available batch-specific documentation should identify the complete Long R3 IGF-I structure, purity, content, and relevant analytical characteristics.

Peptide Lives — peptidelives.com